Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (42)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

  2. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

2023

  1. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

2021

  1. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119

  2. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449

  3. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

  4. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190

  5. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    Radiotherapy and Oncology, Vol. 154, pp. 327-353

  6. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39

  7. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

  8. Prevalence of nodal involvement in rectal cancer after chemoradiotherapy

    The British journal of surgery, Vol. 108, Núm. 10, pp. 1251-1258

2020

  1. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 2, pp. 322-328

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  3. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

    Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479

2019

  1. Agnostic-histology approval of new drugs in oncology: Are we already there?

    Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3210-3219

  2. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

  3. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  4. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2018

  1. Correction to: SEOM clinical guidelines for endometrial cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (29-37), 10.1007/s12094-017-1809-9)

    Clinical and Translational Oncology